Literature DB >> 30537525

Genetic loss of proadrenomedullin N-terminal 20 peptide (PAMP) in mice is compatible with survival.

Brooke C Matson1, Manyu Li2, Claire E Trincot3, Elizabeth S Blakeney3, Stephanie L Pierce4, Kathleen M Caron5.   

Abstract

Adrenomedullin (AM) and proadrenomedullin N-terminal 20 peptide (PAMP) are small peptides derived from a common precursor, pre-proadrenomedullin. Although AM and PAMP share hypotensive effects in the cardiovascular system, the peptides also exert diverse and distinct effects on endocrine physiology, innate immunity, cytoskeletal biology and receptor signaling pathways. Tremendous knowledge has been gleaned from the study of several genetic animal models of AM deletion or overexpression, some of which also simultaneously delete the coding region for PAMP peptide. However, deletion of PAMP without concurrent deletion of AM in an animal model is not currently available for the study of PAMP function. Here, we present the generation of AdmΔPAMPPAMP and AdmΔPAMP/- mice, which lack the coding sequence for PAMP while preserving the coding sequence for AM. AdmΔPAMPPAMP mice survive to adulthood without any obvious abnormalities and are fertile, though AdmΔPAMP/- females have small litters. Interestingly, these animals express lower levels of Adm mRNA and AM peptide than wild type animals, but these levels are still compatible with survival. Importantly, despite reduced levels, the spatiotemporal expression of AM peptide within the hearts of AdmΔPAMP/- mice remains similar to wild type animals. AdmΔPAMPPAMP mice are now a publicly available tool for future investigations of PAMP function.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adrenomedullin; Genetic model; Mouse; PAMP

Mesh:

Substances:

Year:  2018        PMID: 30537525      PMCID: PMC6362461          DOI: 10.1016/j.peptides.2018.11.005

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  30 in total

1.  Overexpression of proadrenomedullin N-terminal 20 peptide blunts blood pressure rise and attenuates myocardial hypertrophy and fibrosis in hypertensive rats.

Authors:  Yuan-Ning Cao; Kenji Kuwasako; Johji Kato; Kensaku Nishihira; Yujiro Asada; Tanenao Eto; Kazuo Kitamura
Journal:  FEBS Lett       Date:  2005-09-12       Impact factor: 4.124

2.  Plasma proadrenomedullin N-terminal 20 peptide (PAMP) in patients with congestive heart failure.

Authors:  T Etoh; J Kato; H Washimine; T Imamura; K Kitamura; Y Koiwaya; K Kangawa; T Eto
Journal:  Horm Metab Res       Date:  1997-01       Impact factor: 2.936

3.  Epicardial-derived adrenomedullin drives cardiac hyperplasia during embryogenesis.

Authors:  Sarah E Wetzel-Strong; Manyu Li; Klara R Klein; Toshio Nishikimi; Kathleen M Caron
Journal:  Dev Dyn       Date:  2014-02       Impact factor: 3.780

4.  Purification and characterization of PAMP-12 (PAMP[9-20]) in porcine adrenal medulla as a major endogenous biologically active peptide.

Authors:  K Kuwasako; K Kitamura; Y Ishiyama; H Washimine; J Kato; K Kangawa; T Eto
Journal:  FEBS Lett       Date:  1997-09-01       Impact factor: 4.124

5.  Proadrenomedullin NH(2)-terminal 20 peptide, a new product of the adrenomedullin gene, inhibits norepinephrine overflow from nerve endings.

Authors:  T Shimosawa; Y Ito; K Ando; K Kitamura; K Kangawa; T Fujita
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

6.  Adrenomedullin and proadrenomedullin N-terminal 20 peptide in impaired renal function.

Authors:  T Eto; H Washimine; J Kato; K Kitamura; Y Yamamoto
Journal:  Kidney Int Suppl       Date:  1996-06       Impact factor: 10.545

7.  Identification of MrgX2 as a human G-protein-coupled receptor for proadrenomedullin N-terminal peptides.

Authors:  Masazumi Kamohara; Ayako Matsuo; Jun Takasaki; Masanobu Kohda; Mitsuyuki Matsumoto; Shun-ichiro Matsumoto; Takatoshi Soga; Hideki Hiyama; Masato Kobori; Masao Katou
Journal:  Biochem Biophys Res Commun       Date:  2005-05-20       Impact factor: 3.575

8.  Effects of PAMP on mRNAs coding for catecholamine-synthesizing enzymes in PC12 cells.

Authors:  K Takekoshi; K Isobe; F Nomura; M Motooka; T Nanmoku; T Nakai
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

9.  Cloning and characterization of cDNA encoding a precursor for human adrenomedullin.

Authors:  K Kitamura; J Sakata; K Kangawa; M Kojima; H Matsuo; T Eto
Journal:  Biochem Biophys Res Commun       Date:  1993-07-30       Impact factor: 3.575

10.  Vascular abnormalities and elevated blood pressure in mice lacking adrenomedullin gene.

Authors:  T Shindo; Y Kurihara; H Nishimatsu; N Moriyama; M Kakoki; Y Wang; Y Imai; A Ebihara; T Kuwaki; K H Ju; N Minamino; K Kangawa; T Ishikawa; M Fukuda; Y Akimoto; H Kawakami; T Imai; H Morita; Y Yazaki; R Nagai; Y Hirata; H Kurihara
Journal:  Circulation       Date:  2001-10-16       Impact factor: 29.690

View more
  1 in total

1.  Proadrenomedullin N-Terminal 20 Peptides (PAMPs) Are Agonists of the Chemokine Scavenger Receptor ACKR3/CXCR7.

Authors:  Max Meyrath; Christie B Palmer; Nathan Reynders; Alain Vanderplasschen; Markus Ollert; Michel Bouvier; Martyna Szpakowska; Andy Chevigné
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.